Table 3.
CG in vitro anti-HIV activities. (AZT, azido-3′-deoxythymidine; ELISA, enzyme-linked immunosorbent assay).
| CG Type | Experimental System | Antiviral Assay | IC50 (µg/mL) | Ref |
|---|---|---|---|---|
| λ-CG | MT-4 cells infected with HIV-HTLVIIIB | Expression of HIV-specific antigens and plaque reduction assays | 9500 (IU/mL) | [61] |
| ι-CG | MT-4 cells infected with HIV | ELISA of p24 antigen | 100 | [56] |
| ι-CG and κ-CG | MT-4 cells and ME-180 cells infected with HIV | ELISA of p24 antigen | 1.6 and 4 | [55] |
| Depolymerized λ-CG | MT-4 cells infected with HIV-HTLVIIIB | Expression of HIV-specific antigens | 3.9 (IC100) | [66] |
| κ-CG and λ-CG | MT-4 cells infected with HIV-HTLVIIIB | Expression of HIV-specific antigens | 12 and 1.9 | [18] |
| κ-CG and AZT conjugates | MT-4 cells infected with HIV (BRU) | Quantitation of virus-induced cytopathicity | 0.1 | [41] |
| λ/κ-CG + MIV-150 | CEM-SS cells infected with HIVMN and HIV-2CDC310342 | Microtiter syncytial assay | 0.1–13.8 | [67] |
| λ/κ-CG (PC-515) | TMZ.bI and DC cells infected with HIV-Bal | Quantitation of β-gal and ELISA of p24 antigen | 0.03–4.17, 1.61 | [12] |
| ι-CG | HeLa-CD4-CCR5 cells infected with HIVJR-FL | Luciferase assay | 1–10 | [68] |
| λ-CG | P4-R5 MAGI cells | ELISA of p24 antigen | 3.7 and 64 | [13] |
| λ-CG | MT-2 cells infected with HIV BaL and IIIB | ELISA of p24 antigen | 0.58 and 0.68 | [14] |